About
LifeBond develops and manufactures medical devices for biosurgery and tissue repair in an effort to save lives and reduce postoperative complications. The proprietary components of the companys product pipeline consist of 100% natural biosurgical materials with an established safety profile. The companys first product, LifeSeal Surgical Sealant, is designed to form a robust reinforcement layer to minimize postoperative complications such as staple-line leakage in bariatric and colorectal procedures. LifeBonds second product, the LifeMesh Self-Fixating Mesh, is intended to provide secure surgical mesh fixation for hernia repair procedures. LifeMesh aims to provide atraumatic tissue fixation through its embedded adhesive layer, and is designed to reduce postsurgical complications associated with penetrative mesh fixation.
Funding history · 5 rounds · $56.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was LifeBond acquired and by which company?
- LifeBond was acquired by Bard Medical in January 2020 for $60 million, leading to its inactive status.
- What was LifeBond's total funding raised before its acquisition?
- LifeBond raised a total of $56.5 million across multiple funding rounds.
- Which investors participated in LifeBond's Series B funding round?
- Pitango VC was an investor in LifeBond's Series B round in January 2009.
- What was the purpose of LifeBond's LifeSeal Surgical Sealant product?
- LifeBond's LifeSeal Surgical Sealant was designed to minimize postoperative complications like staple-line leakage in bariatric and colorectal procedures by forming a robust reinforcement layer.
- What is the function of LifeBond's LifeMesh Self-Fixating Mesh?
- LifeBond's LifeMesh Self-Fixating Mesh provides secure surgical mesh fixation for hernia repair procedures, aiming to reduce postsurgical complications associated with penetrative mesh fixation through its embedded adhesive layer.
- When did LifeBond obtain CE approval for its surgical product?
- LifeBond obtained CE approval for a surgical product in April 2016.
- What was the status of LifeBond's Multi-Center International Pivotal Study for LifeSeal Surgical Sealant in February 2017?
- In February 2017, LifeBond's Multi-Center International Pivotal Study of the LifeSeal Surgical Sealant for GI Resections was enrolling patients in the US and Europe.
- How many employees did LifeBond have at the time of its acquisition?
- LifeBond had 42 employees at the time of its acquisition.